Dorsal root ganglion Spinal dorsal horn Chemotherapy ERK1/2 P38 NFjB a b s t r a c t Toll-like receptor 4 (TLR4) has been implicated as a locus for initiation of paclitaxel related chemotherapy induced peripheral neuropathy (CIPN). This project explores the involvement of the immediate down-stream signal molecules in inducing paclitaxel CIPN. Mitogen-activated protein kinases (MAPKs) and nuclear factor-jB (NFjB) were measured in dorsal root ganglia (DRG) and the spinal cord over time using Western blot and immunohistochemistry in a rat model of paclitaxel CIPN. The effects of MAPK inhibitors in preventing and reversing behavioral signs of CIPN were also measured (group sizes 4-9). Extracellular signal related kinase (ERK1/2) and P38 but not c-Jun N terminal kinase (JNK) or PI3K-Akt signaling expression was increased in DRG. Phospho-ERK1/2 staining was co-localized to small CGRP-positive DRG neurons in cell profiles surrounding large DRG neurons consistent with satellite glial cells. The expression of phospho-P38 was co-localized to small IB4-positive and CGRP-positive DRG neurons. The TLR4 antagonist LPS derived from Rhodobacter sphaeroides (LPS-RS) inhibited paclitaxel-induced phosphorylation of ERK1/2 and P38. The MAPK inhibitors PD98059 (MEK1/2), U0126 (MEK1/2) and SB203580 (P38) prevented but did not reverse paclitaxel-induced behavioral hypersensitivity. Paclitaxel treatment resulted in phosphorylation of Inhibitor a of NFjB (IjBa) in DRG resulting in an apparent release of NFjB from the IjBa-NFjB complex as increased expression of nuclear NFjB was also observed. LPS-RS inhibited paclitaxel-induced translocation of NFjB in DRG. No change was observed in spinal NFjB. These results implicate TLR4 signaling via MAP kinases and NFjB in the induction and maintenance of paclitaxel-related CIPN.
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Introduction
Paclitaxel is the frontline chemotherapeutic agent for many of the most common solid tumors, including those of the breast, ovary, and lung (Hagiwara and Sunada, 2004) . Peripheral neuropathy is the major dose-limiting side effect of paclitaxel and can prompt dose reductions or even the discontinuation of therapy, thus impacting survival in cancer patients (Chaudhry et al., 1994) . Additionally, chemotherapy-induced peripheral neuropathy (CIPN) often persists long after cancer treatment is complete and is commonly refractory to current treatment strategies, thus impacting rehabilitation, the return to productivity and quality of life in cancer survivors (Boyette-Davis et al., 2012; Kosturakis et al., 2014) .
Pro-inflammatory immune responses are thought to play an important role in the underlying basic pathophysiology of neuropathic pain (Austin and Moalem-Taylor, 2010; Vallejo et al., 2010; Zhang et al., 2013) , and evidence implicates similar mechanisms in CIPN (Boyette-Davis and Dougherty, 2011; Boyette-Davis et al., 2011a) . Of note, paclitaxel engages the same signaling
